Literature DB >> 7540943

In the absence of a CD40 signal, B cells are tolerogenic.

J E Buhlmann1, T M Foy, A Aruffo, K M Crassi, J A Ledbetter, W R Green, J C Xu, L D Shultz, D Roopesian, R A Flavell.   

Abstract

When B cells are deprived of signaling through CD40, they exhibit the ability to induce T cell tolerance. The in vivo administration of anti-gp39 and allogeneic B cells diminished the ability of mice to mount an allogeneic response. Tolerance induction was specific for the haplotype expressed on the allogeneic B cells. Selective allospecific unresponsiveness was induced in the CD8 and CD4 compartments by the administration of anti-gp39 and class II-deficient B cells or class I-deficient B cells, respectively. As predicted by studies with anti-gp39 treatment, diminished allospecific responsiveness was induced by the administration of B cells to mice genetically deficient in gp39. Taken together, these data are consistent with the premise that deprivation of CD40 signaling engenders B cells with enhanced tolerogenicity. These studies provide insights into the tolerogenic capacity of resting B cells and outlines a practical approach to exploit this function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540943     DOI: 10.1016/1074-7613(95)90009-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  30 in total

1.  DBC1 is a suppressor of B cell activation by negatively regulating alternative NF-κB transcriptional activity.

Authors:  Sinyi Kong; Muthusamy Thiruppathi; Quan Qiu; Zhenghong Lin; Hongxin Dong; Eduardo N Chini; Bellur S Prabhakar; Deyu Fang
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

2.  Syk mediates BCR- and CD40-signaling integration during B cell activation.

Authors:  Haiyan Ying; Zhenping Li; Lifen Yang; Jian Zhang
Journal:  Immunobiology       Date:  2010-10-07       Impact factor: 3.144

Review 3.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

Review 4.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 5.  T cells of lupus and molecular targets for immunotherapy.

Authors:  S K Datta; A Kaliyaperumal; A Desai-Mehta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

Review 6.  The CD40 ligand. At the center of the immune universe?

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

Review 7.  The anatomy of T-cell activation and tolerance.

Authors:  A Mondino; A Khoruts; M K Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

8.  Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice.

Authors:  G A Holländer; E Castigli; R Kulbacki; M Su; S J Burakoff; J C Gutierrez-Ramos; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 9.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.

Authors:  Y Guo; Y Wu; S Shinde; M S Sy; A Aruffo; Y Liu
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.